

Cosmeceutical evaluation of crocin-rich tomato extract liposomes

*WORKSHOP INVESTIGACIÓN
FACULTAD DE FARMACIA 2024*

María Mondéjar López

BIOFORCE

25 nov 2024




Tomaftran

Anti-inflammatory



Anti-proliferative activities



Neuroprotective




Anti-depressant


Nanotechnology-nanodevices

Organic

Liposomes



Solid lipid NP



Polymeric



Nanocapsule



Nanoemulsion



Nanogel



Inorganic

Au NP



Ag NP



Silica



Carbon-based

Carbon quantum dots



Nanotechnology applications

Cosmeceutics



Biomedicine




Phytosanitary industry





NAPLATEC
BIOTECHNOLOGY & NANOTECHNOLOGY



IBYDA Instituto de
Biotecnología y
Desarrollo Azul



cantabria labs
celebrate life





LabAnalysis
HIGH QUALITY CONTROLS






Bionos
Testing Efficacy



UV damages and UV filters




Cell viability after UVA exposure



Cell viability of human fibroblast exposed to UVB radiation




Nanosystems >>> lipid vesicles >>> liposomes





Folded two-dimensional bilayer forms a three-dimensional hollow vesicle enclosing an aqueous cavity

Transdermal delivery



Liposome formulation





Liposome characterization


<i>Liposomes</i>	<i>Days</i>	<i>Average size (r.nm)</i>	<i>PDI</i>	<i>Z-potential (mV)</i>	<i>%EE</i>	<i>LE%</i>
<i>Un-loaded Liposomes</i>	0	80.71 ± 0.28	0.17 ± 0.02	-34.3 ± 2.8	-	-
	15	83.45 ± 0.61	0.22 ± 0.01	-28.40 ± 0.74	-	-
	30	84.08 ± 0.16	0.342 ± 0.02	10.65 ± 1.77	-	-
<i>Liposomes-TF</i>	0	60.96 ± 0.18	0.06 ± 0.00	-21.50 ± 0.85	16.12 ± 0.02	24.24 ± 0.02
	15	73.10 ± 2.06	0.25 ± 0.03	-27.35 ± 0.21	-	-
	30	63.13 ± 0.35	0.06 ± 0.03	-24.95 ± 4.17	-	-

Liposomes before and after

lyophilization




In vitro release study of Tomaftran- Liposomes



SPF, UVAPF and photoprotection values

	<i>Base</i>	<i>5% TF</i>	<i>10% TF</i>	<i>15% TF</i>	<i>Lipos 10%</i>	<i>Lipos 20%</i>
<i>SPF</i>	1.20 ± 0.00	1.36 ± 0.02	1.46 ± 0.12	1.64 ± 0.12	1.21 ± 0.02	1.22 ± 0.01
<i>UVAPF</i>	1.01 ± 0.00	1.08 ± 0.00	1.12 ± 0.04	1.20 ± 0.05	1.04 ± 0.01	1.03 ± 0
<i>Elastosis</i>	1.03 ± 0.00	1.11 ± 0.01	1.16 ± 0.04	1.24 ± 0.05	1.06 ± 0.01	1.05 ± 0
<i>Photoaging</i>	1.01 ± 0.00	1.08 ± 0.00	1.13 ± 0.04	1.20 ± 0.05	1.04 ± 0.01	1.03 ± 0
<i>Photocarcinogenesis</i>	1.36 ± 0.01	1.57 ± 0.04	1.70 ± 0.20	1.99 ± 0.18	1.34 ± 0.03	1.39 ± 0.03
<i>Immunosuppression</i>	1.29 ± 0.01	1.49 ± 0.03	1.61 ± 0.17	1.85 ± 0.16	1.29 ± 0.03	1.32 ± 0.03
<i>Singlet oxygen</i>	1.01 ± 0.00	1.08 ± 0.00	1.14 ± 0.04	1.23 ± 0.05	1.04 ± 0.01	1.03 ± 0



Proinflammatory levels of Raw 264.7 treated cells after LPS induction



Future perspectives

v Skin permeation assays

v Clinical Efficacy testing





THANK YOU!